• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CONMED Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    4/30/25 4:13:43 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CNMD alert in real time by email
    CNMD 20250430
    false 0000816956 0000816956 2025-04-30 2025-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15 (d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

     

    Date of Report (Date of earliest event reported): April 30, 2025

     

     

    CONMED CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware 001-39218 16-0977505
    (State or other jurisdiction of (Commission File Number) (I.R.S. Employer
    incorporation or organization)   Identification No.)

     

     

    11311 Concept Blvd

    Largo, Florida 33773

    (Address of principal executive offices, including zip code)

     

    (727) 392-6464

    (Registrant's telephone number, including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Rule 12(b) of the Act

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.01 par value CNMD NYSE

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

    Item 2.02Results of Operations and Financial Condition.

     

    On April 30, 2025, CONMED Corporation issued a press release announcing financial results for the first quarter ended March 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1.

     

    The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d)Exhibits

     

    The following exhibits are included herewith:

     

      Exhibit No. Description of Exhibit
      99.1 Press Release dated April 30, 2025, issued by CONMED Corporation.
      104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

     

    Signature

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

         
    Date:     April 30, 2025   CONMED CORPORATION
        (Registrant)
         
         
      By: /s/  Todd W. Garner
      Name: Todd W. Garner
      Title: Executive Vice President, Finance &
        Chief Financial Officer

     

     

     

     

    Get the next $CNMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNMD

    DatePrice TargetRatingAnalyst
    4/28/2025$55.00Buy → Hold
    Stifel
    2/6/2025$85.00 → $70.00Overweight → Neutral
    Analyst
    2/1/2024$119.00 → $129.00Buy
    Needham
    5/22/2023$140.00Buy
    CL King
    3/27/2023$124.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/21/2023$96.00Equal Weight
    Wells Fargo
    10/12/2022$85.00Hold
    Jefferies
    3/2/2022$155.00Neutral
    BofA Securities
    More analyst ratings

    $CNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CONMED downgraded by Stifel with a new price target

      Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00

      4/28/25 8:32:52 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED downgraded by Analyst with a new price target

      Analyst downgraded CONMED from Overweight to Neutral and set a new price target of $70.00 from $85.00 previously

      2/6/25 7:05:01 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Needham reiterated coverage on CONMED with a new price target

      Needham reiterated coverage of CONMED with a rating of Buy and set a new price target of $129.00 from $119.00 previously

      2/1/24 8:15:04 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    SEC Filings

    See more
    • CONMED Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - CONMED Corp (0000816956) (Filer)

      5/21/25 4:03:57 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by CONMED Corporation

      S-8 POS - CONMED Corp (0000816956) (Filer)

      5/20/25 5:13:56 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by CONMED Corporation

      S-8 POS - CONMED Corp (0000816956) (Filer)

      5/20/25 5:12:35 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

      CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

      5/21/25 7:03:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces Quarterly Cash Dividend

      CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as

      5/21/25 7:00:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces First Quarter 2025 Financial Results

      CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. "We had a good start t

      4/30/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Workman John L exercised 479 shares at a strike of $59.84, increasing direct ownership by 2% to 20,891 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/21/25 4:25:37 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by VP GM International Epinette Stephan

      4 - CONMED Corp (0000816956) (Issuer)

      5/15/25 9:59:45 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New insider Epinette Stephan claimed ownership of 15,510 shares (SEC Form 3)

      3 - CONMED Corp (0000816956) (Issuer)

      5/15/25 9:57:36 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Financials

    Live finance-specific insights

    See more
    • CONMED Corporation Announces Quarterly Cash Dividend

      CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as

      5/21/25 7:00:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces First Quarter 2025 Financial Results

      CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. "We had a good start t

      4/30/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025

      CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical t

      4/2/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CONMED Corporation

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      11/13/24 4:22:22 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CONMED Corporation

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      11/12/24 12:53:28 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by CONMED Corporation (Amendment)

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      2/13/24 5:02:29 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/14/24 3:37:54 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/10/24 5:29:04 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/8/24 4:20:48 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Leadership Updates

    Live Leadership Updates

    See more
    • CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

      CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

      5/21/25 7:03:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

      CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

      2/9/21 4:01:00 PM ET
      $CSII
      $MEI
      $CNMD
      Medical/Dental Instruments
      Health Care
      Electrical Products
      Technology